Arlington Trust’s Bio-Rad Laboratories Class A BIO Stock Holding History

Arlington Trust’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7	Closed	-$2.26K	–	533
2023 Q4	$2.26K	Buy	+7	New	+$2.19K	﹤0.01%	607

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Arlington Trust's BIO Position: Q1 2024 in Review

Arlington Trust sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 7 shares — an estimated $2.26K sold.

Arlington Trust first reported a position in BIO in Q4 2023 and held it in 1 quarter. The position peaked at $2.26K in Q4 2023. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

Arlington Trust reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 7 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $2.26K.
Arlington Trust first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and held it in 1 quarter.
Arlington Trust's Bio-Rad Laboratories Class A position peaked at $2.26K in Q4 2023.
466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.